SCHEMBL1347525

SCHEMBL1347525

O=C(CCl)N1CCC(F)(F)C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 2/20 0.41
DPP7 Q9UHL4 2/20 0.41
ALDH1A1 P00352 9/20 0.41
HTT P42858 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
POLB P06746 1/20 0.39
LMNA P02545 2/20 0.37
GRIN2B Q13224 1/20 0.36
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
USP2 O75604 1/20 0.34
CYP3A4 P08684 1/20 0.34
HPGD P15428 1/20 0.34
KMT2A Q03164 1/20 0.34
HSD17B10 Q99714 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
NAMPT P43490 1/20 0.34
IRAK4 Q9NWZ3 1/20 0.33
FAP Q12884 1/20 0.33
HSD11B1 P28845 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4022870 0.88 ALDH1A1 (0.48) ALDH1A1HTTSMN1; SMN2POLBLMNA
SCHEMBL23144924 0.87 ALDH1A1 (0.41) DPP4DPP7ALDH1A1HTTSMN1; SMN2
SCHEMBL16083080 0.83 ALDH1A1 (0.47) DPP4ALDH1A1HTTSMN1; SMN2POLB
SCHEMBL10305031 0.80 OPRM1 (0.50) DPP4DPP7ALDH1A1LMNAGRIN2B
SCHEMBL16215801 0.80 DPP4 (0.41) DPP4DPP7ALDH1A1LMNAGRIN2B
SCHEMBL14305080 0.80 DPP4 (0.45) DPP4DPP7ALDH1A1LMNAGRIN2B
SCHEMBL17057261 0.77 ITGB3 (0.41) DPP4DPP7ALDH1A1LMNAKDM4E
SCHEMBL9946439 0.77 OPRM1 (0.45) DPP4DPP7ALDH1A1POLBLMNA
SCHEMBL12763806 0.77 POLB (0.46) DPP4DPP7ALDH1A1SMN1; SMN2POLB
SCHEMBL5189159 0.77 DPP4 (0.45) DPP4DPP7HPGDNAMPTFAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136598-A1 SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2025-05-01 US disclosed
US-12172997-B2 Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2024-12-24 US disclosed
US-20230250096-A1 SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2023-08-10 US disclosed
US-20230250096-A1 SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2023-08-10 US disclosed
US-20230151006-A1 SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR JANSSEN PHARMACEUTICA NV (BE) 2023-05-18 US disclosed
US-20230151006-A1 SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR JANSSEN PHARMACEUTICA NV (BE) 2023-05-18 US disclosed
US-20230151006-A1 SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR JANSSEN PHARMACEUTICA NV (BE) 2023-05-18 US disclosed
US-11618750-B2 Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2023-04-04 US disclosed
WO-2022253167-A1 SUBSTITUTED PHENYL-1H-PYRROLO [2, 3-c] PYRIDINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2022-12-08 WO disclosed
EP-3983075-A1 SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS Janssen Pharmaceutica NV (BE) 2022-04-20 EP disclosed
WO-2013157562-A1 NITROGENATED BICYCLIC AROMATIC HETEROCYCLIC COMPOUND アステラス製薬株式会社 (JP) 2013-10-24 WO disclosed
US-8063045-B2 Fluoropyrrolidines having dipeptidyl peptidase enzyme inhibitory activity SANOFI-AVENTIS (FR) 2011-11-22 US disclosed
US-20100210838-A1 FLUOROPYRROLIDINES HAVING DIPEPTIDYL PEPTIDASE ENZYME INHIBITORY ACTIVITY SANOFI-AVENTIS (FR) 2010-08-19 US disclosed
US-7655663-B2 Fluoropyrrolidines having dipeptidyl peptidase enzyme inhibitory activity SANOFI-AVENTIS (FR) 2010-02-02 US disclosed
EP-1487807-B1 Cyano-pyrrolidines as DPP-IV inhibitors SANOFI AVENTIS (FR) 2009-09-16 EP disclosed
US-20080161310-A1 FLUOROPYRROLIDINES HAVING DIPEPTIDYL PEPTIDASE ENZYME INHIBITORY ACTIVITY SANOFI-AVENTIS (FR) 2008-07-03 US disclosed
US-7348327-B2 Compounds SANOFI-AVENTIS (FR) 2008-03-25 US disclosed
US-20050130981-A1 Compounds SANOFI-AVENTIS (FR) 2005-06-16 US disclosed
EP-1487807-A2 NEW COMPOUNDS Sanofi-Aventis (FR) 2004-12-22 EP disclosed
WO-2003074500-A2 N-AMINOACETYL-PYRROLIDINE-2-CARBONITRILES AND THEIR USE AS DDP-IV INHIBITORS SANOFI-AVENTIS (FR) 2003-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161310-A1 FLUOROPYRROLIDINES HAVING DIPEPTIDYL PEPTIDASE ENZYME INHIBITORY ACTIVITY DPP4, DPP3, DPP7 DPP4 1/4885DPP7 3/4885ALDH1A1 338/4885
US-20050130981-A1 Compounds DPP4, DPP3, DPP7 DPP4 1/4885DPP7 3/4885ALDH1A1 242/4885
US-12172997-B2 Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators GRIN2B, GRIN2A, GRIN3A DPP4 2266/4885DPP7 2034/4885ALDH1A1 2437/4885
US-20230151006-A1 SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR GRIN2B, GRIN2A, GRIN3A DPP4 1826/4885DPP7 1486/4885ALDH1A1 2278/4885
US-20250136598-A1 SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS GRIN2B, GRIN2A, GRIN3A DPP4 2266/4885DPP7 2034/4885ALDH1A1 2437/4885
US-20230250096-A1 SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVES MLLT1, BMI1, MEN1 DPP4 3032/4885DPP7 2498/4885ALDH1A1 2922/4885
US-20100210838-A1 FLUOROPYRROLIDINES HAVING DIPEPTIDYL PEPTIDASE ENZYME INHIBITORY ACTIVITY DPP4, DPP3, DPP7 DPP4 1/4885DPP7 3/4885ALDH1A1 338/4885
US-11618750-B2 Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators GRIN2B, GRIN2A, GRIN3A DPP4 2266/4885DPP7 2034/4885ALDH1A1 2437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.